<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667602</url>
  </required_header>
  <id_info>
    <org_study_id>V59P22</org_study_id>
    <secondary_id>2007-004754-82</secondary_id>
    <nct_id>NCT00667602</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers</brief_title>
  <official_title>A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The primary immunogenicity objective is to assess and compare the immunogenicity of one dose
      of MenACWY to one dose of Menjugate given to healthy toddlers at 12 months of age as measured
      by the percentage of subjects with serum bactericidal titers directed against N. meningitidis
      serogroup C ≥ 1:8 obtained in the serum bactericidal assay using human complement (hSBA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Subjects With Serum Bactericidal Titer ≥ 1:8 Against N.Meningitidis Serogroup C</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was measured using serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 against N.meningitidis serogroup C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:4 Against N.Meningitidis Serogroup C</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentage of subjects with serum bactericidal activity using human complement (hSBA) titers ≥ 1:4 against N. meningitidis serogroup C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, Y</measure>
    <time_frame>1 month postvaccination.</time_frame>
    <description>Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month postvaccination was assessed and compared as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 vaccine one month postvaccination was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup A, W, Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y</measure>
    <time_frame>1 month postvaccination.</time_frame>
    <description>Immunogenicity for one dose of MenACWY was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8 and titer ≥ 1:4 by serogroups A, W, Y.
Serogroup C is not shown here as it is shown in other outcome measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Serum Bactericidal Activity Geometric Mean Titers After One Dose of MenACWY-CRM197 and MenC Against N.Meningitidis Serogroup C</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed with geometric mean titer (GMT) of serum bactericidal assay with human complement (hSBA) against N. meningitidis serogroup C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 one month postvaccination was assessed with GMT of serum bactericidal assay with hSBA against Serogroups A, W, Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, C, W, Y</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed and compared as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroup C.
The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroups A, W, Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Seroresponse Rates After One Dose of DTPa-IPV-HepB-Hib (Concomitant Vaccine)</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>The immunogenicity of one dose of MenC to one dose of DTPa-IPV-HepB-Hib concomitant vacccine was assessed.
For Pertussis antigens, Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN), the seroresponse in initially seronegative subjects (pre-vaccination antibody concentration &lt; LLQ) is defined as post-vaccination antibody concentration &gt;= LLQ; in initially seropositive subjects (pre-vaccination antibody concentration &gt;=LLQ) seroresponse is defined as at least two fold increase of the pre-vaccination antibody concentration.
Diptheria and Tetanus: primary endpoint ELISA (Enzyme-linked immunosorbent assay) &gt;=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA&gt;=1.0 IU/mL.
Polio type 1, 2 and 3: bNT (neutralization test) with &gt;=1:8.
HepB (HBV): primary endpoint ELISA &gt;=10mU/mL.
PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Seroresponse Rates After One Dose of PCV7 (Concomitant Vaccine)</measure>
    <time_frame>1 month postvaccination</time_frame>
    <description>To compare the immunogenicity of PCV7 (Pneumococcal 7-valent Conjugate)Vaccine when given concomitantly with one dose or two doses of MenACWY-CRM197 or with MenC to infants at 12 months of age.
Seroresponse for PCV7 (PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F, PnC 23F) is defined as: a subject with primary endpoint ELISA ≥ 0.35 mcg/mL and secondary endpoint ELISA ≥ 1.0 mcg/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroup C</measure>
    <time_frame>1 month postvaccination and 6-18 months postvaccination.</time_frame>
    <description>Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titers ≥ 1:8, and titers ≥ 1:4 directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 ,and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y</measure>
    <time_frame>1 month postvaccination 6-18 months postvaccination</time_frame>
    <description>Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 and titer ≥ 1:4 directed against N. meningitidis serogroups A, W and Y (only for subjects enrolled in Australia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C</measure>
    <time_frame>1 month postvaccination and 6-18 months postvaccination.</time_frame>
    <description>Persistence of immunogenicity of either one or two doses of MenACWY or one dose of MenC as measured by human serum bactericidal activity geometric mean titers directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y</measure>
    <time_frame>6-18 months postvaccination.</time_frame>
    <description>Immunogenicity of two doses of MenACWY to one dose of MenACWY as measured by hSBA GMTs directed against N.meningitidis serogroups A, W, Y (only for subjects enrolled in Australia).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128 and Four Fold Rise Against N.Meningitidis Serogroup C</measure>
    <time_frame>1 month postvaccination.</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128, and Four Fold Rise Against N.Meningitidis Serogroup A, W, Y</measure>
    <time_frame>1 month postvaccination.</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.
Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C</measure>
    <time_frame>1 month postvaccination.</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup A, W, Y</measure>
    <time_frame>1 month postvaccination.</time_frame>
    <description>Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with GMT of SBA with rabbit complement (rSBA) against Serogroup A, W, Y.
Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup A, W, Y.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 to Day 7 Postvaccination), After Any Vaccination</measure>
    <time_frame>From day 1 to day 7 postvaccination</time_frame>
    <description>Safety was assessed as the number of subjects who reported solicited local reactions from day 1 to day 7 postvaccination for all the three vaccination groups.
safety was assessed as the number of subjects who reported solicited systemic reactions from day 1 to day 7 Following the Month 12 vaccination in all three vaccination groups</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">662</enrollment>
  <condition>Meningococcal Meningitis</condition>
  <arm_group>
    <arm_group_label>MenACWY-CRM197 (2 doses) + Concomitant Vaccines</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received two doses of MenACWY-CRM197 at 6 to 8 and 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenACWY-CRM197 (1 dose) + Concomitant Vaccines</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infants received one dose of MenACWY-CRM197 at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MenC (1 dose) + Concomitant Vaccines</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Infants received one dose of MenC vaccine at 12 months of age and concomitant dose of PCV7 (Pneumococcal 7-valent Conjugate Vaccine) and DTPa-IPV-HepB-Hib (Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b) at 12 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM197 (two doses)</intervention_name>
    <description>Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.</description>
    <arm_group_label>MenACWY-CRM197 (2 doses) + Concomitant Vaccines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenC</intervention_name>
    <description>One 0.5mL dose of MenC vaccine was administered by intramuscular injection.</description>
    <arm_group_label>MenC (1 dose) + Concomitant Vaccines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV7</intervention_name>
    <description>One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.</description>
    <arm_group_label>MenACWY-CRM197 (2 doses) + Concomitant Vaccines</arm_group_label>
    <arm_group_label>MenACWY-CRM197 (1 dose) + Concomitant Vaccines</arm_group_label>
    <arm_group_label>MenC (1 dose) + Concomitant Vaccines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPa-IPV-HepB-Hib</intervention_name>
    <description>One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.</description>
    <arm_group_label>MenACWY-CRM197 (2 doses) + Concomitant Vaccines</arm_group_label>
    <arm_group_label>MenACWY-CRM197 (1 dose) + Concomitant Vaccines</arm_group_label>
    <arm_group_label>MenC (1 dose) + Concomitant Vaccines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MenACWY-CRM197 (one dose)</intervention_name>
    <description>One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.</description>
    <arm_group_label>MenACWY-CRM197 (1 dose) + Concomitant Vaccines</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infants 6 to 8 months old inclusive, who were born after full term pregnancy and
             previously received three doses of both Prevenar and Infanrix-hexa vaccines at least
             30 days before study entry

        Exclusion Criteria:

          -  who previously received any meningococcal vaccine;

          -  who have had a previous confirmed or suspected disease caused by N. meningitidis, C.
             diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis;

          -  who have had household contact with and/or intimate exposure to an individual with
             laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib,
             C. diphtheriae, Polio, or pneumococcal infection at any time since birth;

          -  Subjects with any serious, acute or chronic progressive disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>8 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Bad Kreuznach</city>
        <zip>55543</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38</name>
      <address>
        <city>Bad Lobenstein</city>
        <zip>07356</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Balve</city>
        <zip>58802</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 3</name>
      <address>
        <city>Berlin</city>
        <zip>12589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Berlin</city>
        <zip>12619</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Berlin</city>
        <zip>13189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Berlin</city>
        <zip>13189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Bönnigheim</city>
        <zip>74357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 39</name>
      <address>
        <city>Eschwege</city>
        <zip>37269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Flensburg</city>
        <zip>24937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Frankenthal</city>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Glücksburg</city>
        <zip>24960</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Hamburg</city>
        <zip>22147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 2</name>
      <address>
        <city>Kehl</city>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Mainz</city>
        <zip>55127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43</name>
      <address>
        <city>München-Ramersdorf</city>
        <zip>81669</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42</name>
      <address>
        <city>Neuhaus am Rennweg</city>
        <zip>98724</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Neumünster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 9</name>
      <address>
        <city>Neumünster</city>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Oberstenfeld</city>
        <zip>71720</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 4</name>
      <address>
        <city>Stuttgart</city>
        <zip>70193</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Stuttgart</city>
        <zip>70469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Weilheim i OB</city>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6</name>
      <address>
        <city>Wiesloch</city>
        <zip>69168</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <results_first_submitted>February 18, 2013</results_first_submitted>
  <results_first_submitted_qc>September 3, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 7, 2013</results_first_posted>
  <disposition_first_submitted>February 18, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 25, 2011</disposition_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal</keyword>
  <keyword>ACWY</keyword>
  <keyword>Conjugate Vaccine</keyword>
  <keyword>Meningitis</keyword>
  <keyword>Toddlers</keyword>
  <keyword>Infants</keyword>
  <keyword>Concomitant Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis</mesh_term>
    <mesh_term>Meningitis, Meningococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>All participants enrolled were included in the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
          <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
        <group group_id="P2">
          <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
          <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
        <group group_id="P3">
          <title>MenC (1dose) + Concomitant Vaccines</title>
          <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="228"/>
                <participants group_id="P3" count="215"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="213"/>
                <participants group_id="P3" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>As one site has been excluded, the number of subjects included in the analysis are MenACWY-CRM197 (2dose) + Concomitant Vaccines N= 196, MenACWY-CRM197 (1dose) + Concomitant Vaccines N= 205 and MenC (1dose) + Concomitant Vaccines N= 193</population>
      <group_list>
        <group group_id="B1">
          <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
          <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
        <group group_id="B2">
          <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
          <description>Infants received one dose of MenACWY-CRM197 at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
        <group group_id="B3">
          <title>MenC (1dose) + Concomitant Vaccines</title>
          <description>Infants received one dose of MenC vaccine at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="219"/>
            <count group_id="B2" value="228"/>
            <count group_id="B3" value="215"/>
            <count group_id="B4" value="662"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="208.4" spread="23.7"/>
                    <measurement group_id="B2" value="209.8" spread="22.2"/>
                    <measurement group_id="B3" value="209.3" spread="21.9"/>
                    <measurement group_id="B4" value="209.2" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Serum Bactericidal Titer ≥ 1:8 Against N.Meningitidis Serogroup C</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was measured using serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 against N.meningitidis serogroup C.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>Analysis was done on the per-protocol (PP) set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Serum Bactericidal Titer ≥ 1:8 Against N.Meningitidis Serogroup C</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was measured using serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 against N.meningitidis serogroup C.</description>
          <population>Analysis was done on the per-protocol (PP) set, i.e. the subjects who received the vaccine correctly; provided evaluable serum samples at the relevant time points; and had no major protocol violations as defined prior to analysis.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="77" upper_limit="89"/>
                    <measurement group_id="O2" value="92" lower_limit="86" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary criterion for immunogenicity was that the lower limit of the two-sided 95% confidence interval (CI) for the difference between one dose of MenACWY-CRM197 and MenC in the percentage of subjects with hSBA ≥1:8 for serogroup C at 1 month following the 12 months vaccination was greater than -10% .</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC)</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:4 Against N.Meningitidis Serogroup C</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentage of subjects with serum bactericidal activity using human complement (hSBA) titers ≥ 1:4 against N. meningitidis serogroup C.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:4 Against N.Meningitidis Serogroup C</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentage of subjects with serum bactericidal activity using human complement (hSBA) titers ≥ 1:4 against N. meningitidis serogroup C.</description>
          <population>Analysis was done on PP set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="85" upper_limit="94"/>
                    <measurement group_id="O2" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary criterion for immunogenicity was that the lower limit of the two-sided 95% confidence interval (CI) for the difference between one dose of MenACWY-CRM197 and MenC in the percentage of subjects with hSBA ≥ 1:4 for serogroup C at 1 month following the 12 months vaccination was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC)</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <ci_upper_limit>-2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, Y</title>
        <description>Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month postvaccination was assessed and compared as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 vaccine one month postvaccination was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup A, W, Y.</description>
        <time_frame>1 month postvaccination.</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, C, W, Y</title>
          <description>Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month postvaccination was assessed and compared as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 vaccine one month postvaccination was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8, ≥ 1:4 against N.meningitidis Serogroup A, W, Y.</description>
          <population>Analysis was done on PP set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>titer ≥ 1:8, prevacc, Men A, (N=159,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" lower_limit="15" upper_limit="29"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, postvacc, Men A (N=166,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="88" upper_limit="97"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, prevacc, Men C (N=161,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="71" upper_limit="84"/>
                    <measurement group_id="O2" value="6" lower_limit="3" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, postvacc, Men C (N=167,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="92" lower_limit="86" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, prevacc, Men W, (N=157,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" lower_limit="60" upper_limit="75"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, postvacc, Men W, (N=165,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, prevacc, Men Y, (N=156, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="61" upper_limit="76"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, postvacc, Men Y, (N=163,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, prevacc, Men A, (N=159,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="19" upper_limit="33"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, postvacc, Men A, (N=166,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="91" upper_limit="98"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, prevacc, Men C, (N=161,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="81" upper_limit="92"/>
                    <measurement group_id="O2" value="7" lower_limit="4" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, postvacc, Men C, (N=167,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, prevacc, Men W, (N=157,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" lower_limit="66" upper_limit="81"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, postvacc, Men W, (N=165,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, prevacc, Men Y, (N=156,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="71" upper_limit="84"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, postvacc, Men Y, (N=163,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="5" lower_limit="0" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons to MenC were based on the percentages of subjects with response (hSBA ≥1:8, prevaccination) to serogroup C. MenACWY was determined to be noninferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY and MenC in the percentage of subjects with response towards serogroup C was greater than –10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PMenACWY – PMenC &gt; -10%).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>64</ci_lower_limit>
            <ci_upper_limit>79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons to MenC were based on the percentages of subjects with response (hSBA ≥1:8, one month postvaccination) to serogroup C. MenACWY was determined to be noninferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY and MenC in the percentage of subjects with response towards serogroup C was greater than –10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PMenACWY – PMenC &gt; -10%).</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons to MenC were based on the percentages of subjects with response (hSBA ≥1:4, prevaccination) to serogroup C. MenACWY was determined to be noninferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY and MenC in the percentage of subjects with response towards serogroup C was greater than –10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PMenACWY – PMenC &gt; -10%).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73</ci_lower_limit>
            <ci_upper_limit>86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons to MenC were based on the percentages of subjects with response (hSBA ≥1:4, one month postvaccination) to serogroup C. MenACWY was determined to be noninferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY and MenC in the percentage of subjects with response towards serogroup C was greater than –10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PMenACWY – PMenC &gt; -10%).</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y</title>
        <description>Immunogenicity for one dose of MenACWY was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8 and titer ≥ 1:4 by serogroups A, W, Y.
Serogroup C is not shown here as it is shown in other outcome measures.</description>
        <time_frame>1 month postvaccination.</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y</title>
          <description>Immunogenicity for one dose of MenACWY was assessed as percentages of subjects with serum bactericidal titer with human complement (hSBA) ≥ 1:8 and titer ≥ 1:4 by serogroups A, W, Y.
Serogroup C is not shown here as it is shown in other outcome measures.</description>
          <population>Analysis was done on PP set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>titer ≥ 1:8, pre-vacc, Men A, (N=171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.015" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, post-vacc, Men A, (N=172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" lower_limit="41" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, pre-vacc, Men W, (N=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, post-vacc, Men W, (N=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="53" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, pre-vacc, Men Y, (N=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:8, post-vacc, Men Y, (N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="42" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, pre-vacc, Men A, (N=171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0.015" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, post-vacc, Men A, (N=172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="50" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, pre-vacc, Men W, (N=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="1" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, post-vacc, Men W, (N=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62" lower_limit="55" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, pre-vacc, Men Y, (N=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>titer ≥ 1:4, post-vacc, Men Y, (N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" lower_limit="48" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Serum Bactericidal Activity Geometric Mean Titers After One Dose of MenACWY-CRM197 and MenC Against N.Meningitidis Serogroup C</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed with geometric mean titer (GMT) of serum bactericidal assay with human complement (hSBA) against N. meningitidis serogroup C.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Serum Bactericidal Activity Geometric Mean Titers After One Dose of MenACWY-CRM197 and MenC Against N.Meningitidis Serogroup C</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed with geometric mean titer (GMT) of serum bactericidal assay with human complement (hSBA) against N. meningitidis serogroup C.</description>
          <population>Analysis was done on PP set.</population>
          <units>Titers</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prevaccination (month 12) (N=174, 152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" lower_limit="1.77" upper_limit="2.51"/>
                    <measurement group_id="O2" value="2.29" lower_limit="1.9" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postvaccination (month 13) (N=175,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="18" upper_limit="28"/>
                    <measurement group_id="O2" value="31" lower_limit="24" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For comparison of the Geometric Mean Titers, prevaccination at 12 months of age, MenACWY–CRM197 was determined to be non-inferior to MenC if the lower limit of the 2-sided 95% CI for the ratio of the MenACWY-CRM197 to MenC Geometric Mean Titers for serogroup C was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(GMTMenACWY/GMTMenC &gt; 0.5).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For comparison of the Geometric Mean Titers, one month postvaccination at 12 months of age, MenACWY–CRM197 was determined to be non-inferior to MenC if the lower limit of the 2-sided 95% CI for the ratio of the MenACWY-CRM197 to MenC Geometric Mean Titers for serogroup C was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(GMTMenACWY/GMTMenC &gt; 0.5).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 one month postvaccination was assessed with GMT of serum bactericidal assay with hSBA against Serogroups A, W, Y.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 one month postvaccination was assessed with GMT of serum bactericidal assay with hSBA against Serogroups A, W, Y.</description>
          <population>Analysis was done on PP set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>prevacc, Men A (N=171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" lower_limit="1.72" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postvacc Men A (N=172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7.71" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>prevacc, Men W (N=168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.71" upper_limit="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postvacc Men W (N=170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="10" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>prevacc, Men Y (N=160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.59" upper_limit="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postvacc Men Y (N=167)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" lower_limit="5.43" upper_limit="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, C, W, Y</title>
        <description>The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed and compared as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroup C.
The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroups A, W, Y.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, C, W, Y</title>
          <description>The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed and compared as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroup C.
The immunogenicity of two doses of MenACWY-CRM197, to a single dose of MenC was assessed as measured by human Serum Bactericidal Activity Geometric Mean Titers directed against N. meningitidis serogroups A, W, Y.</description>
          <population>Analysis was done on PP set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>prevacc, Men A (N=159,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.92" upper_limit="3.97"/>
                    <measurement group_id="O2" value="2" lower_limit="1.46" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postvacc Men A (N=166,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="56" upper_limit="99"/>
                    <measurement group_id="O2" value="2.22" lower_limit="1.22" upper_limit="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>prevacc, Men C (N=161,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" lower_limit="19" upper_limit="28"/>
                    <measurement group_id="O2" value="2.29" lower_limit="1.9" upper_limit="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postvacc, Men C (N=167,153)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249" lower_limit="197" upper_limit="314"/>
                    <measurement group_id="O2" value="31" lower_limit="24" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>prevacc, Men W (N=157,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="O2" value="1.71" lower_limit="1.06" upper_limit="2.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postvacc, Men W (N=165,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="213" lower_limit="153" upper_limit="295"/>
                    <measurement group_id="O2" value="2" lower_limit="0.99" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>prevacc, Men Y (N=156,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="9.44" upper_limit="14"/>
                    <measurement group_id="O2" value="1.76" lower_limit="1.18" upper_limit="2.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>postvacc, Men Y (N=163,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156" lower_limit="119" upper_limit="205"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.06" upper_limit="3.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For comparison of the GMTs (prevaccination), MenACWY was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the ratio of the MenACWY to MenC GMTs for serogroup C was greater than 0.5 .</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(GMTMenACWY/GMTMenjugate &gt; 0.5).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.43</ci_lower_limit>
            <ci_upper_limit>13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For comparison of the GMTs (one month postvaccination), MenACWY was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the ratio of the MenACWY to MenC GMTs for serogroup C was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(GMTMenACWY/GMTMenjugate &gt; 0.5).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>8.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.35</ci_lower_limit>
            <ci_upper_limit>10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Seroresponse Rates After One Dose of DTPa-IPV-HepB-Hib (Concomitant Vaccine)</title>
        <description>The immunogenicity of one dose of MenC to one dose of DTPa-IPV-HepB-Hib concomitant vacccine was assessed.
For Pertussis antigens, Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN), the seroresponse in initially seronegative subjects (pre-vaccination antibody concentration &lt; LLQ) is defined as post-vaccination antibody concentration &gt;= LLQ; in initially seropositive subjects (pre-vaccination antibody concentration &gt;=LLQ) seroresponse is defined as at least two fold increase of the pre-vaccination antibody concentration.
Diptheria and Tetanus: primary endpoint ELISA (Enzyme-linked immunosorbent assay) &gt;=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA&gt;=1.0 IU/mL.
Polio type 1, 2 and 3: bNT (neutralization test) with &gt;=1:8.
HepB (HBV): primary endpoint ELISA &gt;=10mU/mL.
PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and concomitant dose of PCV7 and DTPa-IPV-HepBHib at 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Seroresponse Rates After One Dose of DTPa-IPV-HepB-Hib (Concomitant Vaccine)</title>
          <description>The immunogenicity of one dose of MenC to one dose of DTPa-IPV-HepB-Hib concomitant vacccine was assessed.
For Pertussis antigens, Pertussis Toxin (PT), Filamentous Hemagglutinin (FHA) and Pertactin (PRN), the seroresponse in initially seronegative subjects (pre-vaccination antibody concentration &lt; LLQ) is defined as post-vaccination antibody concentration &gt;= LLQ; in initially seropositive subjects (pre-vaccination antibody concentration &gt;=LLQ) seroresponse is defined as at least two fold increase of the pre-vaccination antibody concentration.
Diptheria and Tetanus: primary endpoint ELISA (Enzyme-linked immunosorbent assay) &gt;=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA&gt;=1.0 IU/mL.
Polio type 1, 2 and 3: bNT (neutralization test) with &gt;=1:8.
HepB (HBV): primary endpoint ELISA &gt;=10mU/mL.
PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.</description>
          <population>Analysis was done on PP set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Diphtheria Toxin ≥ 0.1 IU/mL N= (168,173,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Diphtheria Toxin ≥ 1.0 IU/mL N= (168,173,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="98" lower_limit="94" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Toxin ≥ 0.1 IU/mL N= (168,173,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Tetanus Toxin ≥ 1.0 IU/mL N= (168,173,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="92" upper_limit="98"/>
                    <measurement group_id="O2" value="96" lower_limit="92" upper_limit="98"/>
                    <measurement group_id="O3" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FHA ELISA N=(160,169,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="91" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O3" value="96" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PRN ELISA N=(160,169,152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="94" upper_limit="99"/>
                    <measurement group_id="O3" value="99" lower_limit="95" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT ELISA N=(159,165,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="93" upper_limit="99"/>
                    <measurement group_id="O2" value="95" lower_limit="90" upper_limit="97"/>
                    <measurement group_id="O3" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>polio 1 N=(157,161,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>polio 2 N=157,(161,148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>polio 3 N=(146,151,143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="97" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hep B N=(157,161,147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP (HIB) ≥ 0.15 μg/mL N=(168,173,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="98" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP (HIB) ≥ 1.0 μg/mL N=(168,173,151)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="98" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Diptheria Toxin ≥0.1 IU/mL, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Diptheria Toxin ≥0.1 IU/mL, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Diptheria Toxin ≥1.0 IU/mL, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Diptheria Toxin ≥1.0 IU/mL, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Tetanus Toxin ≥ 0.1 IU/mL, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Tetanus Toxin ≥ 0.1 IU/mL, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, for any of the antigens, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Tetanus Toxin ≥ 1.0 IU/mL, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti-Tetanus Toxin ≥ 1.0 IU/mL, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (polio 1, one month postvaccination), given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (polio 1, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (polio 2, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (polio 2, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (polio 3, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Polio 3, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti- PRP ≥ 0.15 μg/mL, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti- PRP ≥ 0.15 μg/mL, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti- PRP ≥ 1.0 μg/mL, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Anti- PRP ≥ 1.0 μg/mL, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Hep B, one month postvaccination) given concomitantly with two dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of DTPa-IPV-HepB-Hib (Hep B, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to DTPa-IPV-HepB-Hib given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC)</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Seroresponse Rates After One Dose of PCV7 (Concomitant Vaccine)</title>
        <description>To compare the immunogenicity of PCV7 (Pneumococcal 7-valent Conjugate)Vaccine when given concomitantly with one dose or two doses of MenACWY-CRM197 or with MenC to infants at 12 months of age.
Seroresponse for PCV7 (PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F, PnC 23F) is defined as: a subject with primary endpoint ELISA ≥ 0.35 mcg/mL and secondary endpoint ELISA ≥ 1.0 mcg/mL.</description>
        <time_frame>1 month postvaccination</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Seroresponse Rates After One Dose of PCV7 (Concomitant Vaccine)</title>
          <description>To compare the immunogenicity of PCV7 (Pneumococcal 7-valent Conjugate)Vaccine when given concomitantly with one dose or two doses of MenACWY-CRM197 or with MenC to infants at 12 months of age.
Seroresponse for PCV7 (PnC 4, PnC 6B, PnC 9V, PnC 14, PnC 18C, PnC 19F, PnC 23F) is defined as: a subject with primary endpoint ELISA ≥ 0.35 mcg/mL and secondary endpoint ELISA ≥ 1.0 mcg/mL.</description>
          <population>Analysis was done on PP set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PNC 4 N=(168,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="76" upper_limit="88"/>
                    <measurement group_id="O2" value="82" lower_limit="75" upper_limit="88"/>
                    <measurement group_id="O3" value="87" lower_limit="81" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PNC 6B N=(168,149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="87" upper_limit="96"/>
                    <measurement group_id="O2" value="91" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O3" value="97" lower_limit="93" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PNC 9V N=(168,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="85" upper_limit="94"/>
                    <measurement group_id="O2" value="89" lower_limit="83" upper_limit="93"/>
                    <measurement group_id="O3" value="93" lower_limit="88" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PNC 14 N=(167,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" lower_limit="96" upper_limit="100"/>
                    <measurement group_id="O2" value="99" lower_limit="97" upper_limit="100"/>
                    <measurement group_id="O3" value="99" lower_limit="96" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PNC 18C N=(168,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="63" upper_limit="77"/>
                    <measurement group_id="O2" value="76" lower_limit="68" upper_limit="82"/>
                    <measurement group_id="O3" value="86" lower_limit="79" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PNC 19 F N=(168,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="74" upper_limit="87"/>
                    <measurement group_id="O2" value="80" lower_limit="74" upper_limit="86"/>
                    <measurement group_id="O3" value="90" lower_limit="84" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PNC 23 F N=(168,150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="82" upper_limit="92"/>
                    <measurement group_id="O2" value="89" lower_limit="83" upper_limit="93"/>
                    <measurement group_id="O3" value="94" lower_limit="89" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC4, one month postvaccination)given concomitantly with one dose of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7(PNC 6B, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7(PnC 9V, one month postvaccination) given concomitantly with MenACWY-CRM197 or MenC was considered non-inferior, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC 14, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7( PNC 18C, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19</ci_lower_limit>
            <ci_upper_limit>-2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC 19F, one month postvaccination), given concomitantly with one dose of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17</ci_lower_limit>
            <ci_upper_limit>-2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC 23F, one month postvaccination) given concomitantly with one dose of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC4, one month postvaccination) given concomitantly with two doses of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC6B, one month postvaccination) given concomitantly with two doses of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC 9V, one month postvaccination) given concomitantly with two doses of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC14, one month postvaccination) given concomitantly with two doses of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4</ci_lower_limit>
            <ci_upper_limit>3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC18C, one month postvaccination) given concomitantly with two doses of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24</ci_lower_limit>
            <ci_upper_limit>-6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC19F, one month postvaccination) given concomitantly with two doses of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17</ci_lower_limit>
            <ci_upper_limit>-1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Immunogenicity of PCV7 (PNC23F, one month postvaccination) given concomitantly with two doses of MenACWY was considered non-inferior to PCV7 given concomitantly with one dose of MenC, if the lower limit of the two-sided 95% CI for the difference in the percentage of subjects with antibody response was greater than the cut-off level specified for that antigen was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY - PConcomitant Vaccine+MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroup C</title>
        <description>Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titers ≥ 1:8, and titers ≥ 1:4 directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).</description>
        <time_frame>1 month postvaccination and 6-18 months postvaccination.</time_frame>
        <population>Analysis was done on PP set (persistence subgroup).</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 and Titer ≥ 1:4 Against N. Meningitidis Serogroup C</title>
          <description>Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titers ≥ 1:8, and titers ≥ 1:4 directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).</description>
          <population>Analysis was done on PP set (persistence subgroup).</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥ 1:8, postvacc, Men C. N=(17,14,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="86" lower_limit="57" upper_limit="98"/>
                    <measurement group_id="O3" value="92" lower_limit="64" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:8, perisistence, Men C. N=(17,14,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" lower_limit="44" upper_limit="90"/>
                    <measurement group_id="O2" value="64" lower_limit="35" upper_limit="87"/>
                    <measurement group_id="O3" value="54" lower_limit="25" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, postvacc, Men C. N=(17,14,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="93" lower_limit="66" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="75" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, persistence, Men C. N=(17,14,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="50" upper_limit="93"/>
                    <measurement group_id="O2" value="71" lower_limit="42" upper_limit="92"/>
                    <measurement group_id="O3" value="77" lower_limit="46" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 ,and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y</title>
        <description>Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 and titer ≥ 1:4 directed against N. meningitidis serogroups A, W and Y (only for subjects enrolled in Australia).</description>
        <time_frame>1 month postvaccination 6-18 months postvaccination</time_frame>
        <population>Analysis was done on PP set (persistence subset).</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Immune Response Measured as Percentages of Subjects With Human Serum Bactericidal Titer ≥ 1:8 ,and Titer ≥ 1:4 Against N. Meningitidis Serogroups A, W, Y</title>
          <description>Persistence of immune response to either one or two doses of MenACWY-CRM197 or one dose of MenC as measured by serum bactericidal assay with human complement (hSBA) titer ≥ 1:8 and titer ≥ 1:4 directed against N. meningitidis serogroups A, W and Y (only for subjects enrolled in Australia).</description>
          <population>Analysis was done on PP set (persistence subset).</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>hSBA ≥ 1:8, postvacc, Men A (N=17,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="64" upper_limit="99"/>
                    <measurement group_id="O2" value="42" lower_limit="15" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:8, persistence, Men A (N=16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="11" upper_limit="59"/>
                    <measurement group_id="O2" value="7" lower_limit="0" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, post-vacc, Men A (N=17,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="50" lower_limit="21" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, persistence, Men A (N=16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="15" upper_limit="65"/>
                    <measurement group_id="O2" value="14" lower_limit="2" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:8, postvacc, Men W (N=17,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="67" lower_limit="35" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:8, persistence, Men W (N=16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="48" upper_limit="93"/>
                    <measurement group_id="O2" value="71" lower_limit="42" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, postvacc, Men W (N=17,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="57" upper_limit="98"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, persistence, Men W (N=16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="62" upper_limit="98"/>
                    <measurement group_id="O2" value="71" lower_limit="42" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:8, postvacc, Men Y (N=17,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="33" lower_limit="10" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:8, persistence, Men Y (N=14,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="49" upper_limit="95"/>
                    <measurement group_id="O2" value="79" lower_limit="49" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, postvacc, Men Y (N=17,12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="50" lower_limit="21" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hSBA ≥ 1:4, persistence, Men Y (N=14,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="57" upper_limit="98"/>
                    <measurement group_id="O2" value="93" lower_limit="66" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C</title>
        <description>Persistence of immunogenicity of either one or two doses of MenACWY or one dose of MenC as measured by human serum bactericidal activity geometric mean titers directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).</description>
        <time_frame>1 month postvaccination and 6-18 months postvaccination.</time_frame>
        <population>Analysis was done on PP set (subjects enrolled in Australia).</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MenC(1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C</title>
          <description>Persistence of immunogenicity of either one or two doses of MenACWY or one dose of MenC as measured by human serum bactericidal activity geometric mean titers directed against N.meningitidis serogroup C (only for subjects enrolled in Australia).</description>
          <population>Analysis was done on PP set (subjects enrolled in Australia).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="241" lower_limit="139" upper_limit="419"/>
                    <measurement group_id="O2" value="36" lower_limit="19" upper_limit="66"/>
                    <measurement group_id="O3" value="30" lower_limit="16" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 18 months after month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="7.45" upper_limit="29"/>
                    <measurement group_id="O2" value="12" lower_limit="5.65" upper_limit="25"/>
                    <measurement group_id="O3" value="8.95" lower_limit="4.15" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y</title>
        <description>Immunogenicity of two doses of MenACWY to one dose of MenACWY as measured by hSBA GMTs directed against N.meningitidis serogroups A, W, Y (only for subjects enrolled in Australia).</description>
        <time_frame>6-18 months postvaccination.</time_frame>
        <population>Analysis was done on PP set (only for subjects enrolled in Australia).</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Persistence of Human Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroups A, W, Y</title>
          <description>Immunogenicity of two doses of MenACWY to one dose of MenACWY as measured by hSBA GMTs directed against N.meningitidis serogroups A, W, Y (only for subjects enrolled in Australia).</description>
          <population>Analysis was done on PP set (only for subjects enrolled in Australia).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12, Ser A (N= 17, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="26" upper_limit="86"/>
                    <measurement group_id="O2" value="6.69" lower_limit="3.28" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 18 months after Month 12, Ser A (N=16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" lower_limit="2.78" upper_limit="7"/>
                    <measurement group_id="O2" value="2.78" lower_limit="1.7" upper_limit="4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Ser W (N= 17, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180" lower_limit="95" upper_limit="340"/>
                    <measurement group_id="O2" value="13" lower_limit="6.26" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 18 months after Month 12, Ser W (N=16,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="10" upper_limit="39"/>
                    <measurement group_id="O2" value="20" lower_limit="9.77" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12, Ser Y (N= 17, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="93" upper_limit="246"/>
                    <measurement group_id="O2" value="5.13" lower_limit="2.87" upper_limit="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - 18 months after Month 12, Ser Y (N=14,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="12" upper_limit="38"/>
                    <measurement group_id="O2" value="16" lower_limit="9.15" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128 and Four Fold Rise Against N.Meningitidis Serogroup C</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.</description>
        <time_frame>1 month postvaccination.</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128 and Four Fold Rise Against N.Meningitidis Serogroup C</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup C.</description>
          <population>Analysis was done on PP set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA titer ≥ 1:8, prevacc (N=140,140,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="64" upper_limit="79"/>
                    <measurement group_id="O2" value="4" lower_limit="1" upper_limit="8"/>
                    <measurement group_id="O3" value="1" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:8, postvacc (N=156,157,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="94" upper_limit="100"/>
                    <measurement group_id="O2" value="92" lower_limit="86" upper_limit="96"/>
                    <measurement group_id="O3" value="97" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:128, prevacc (N=140,140,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="23" upper_limit="39"/>
                    <measurement group_id="O2" value="1" lower_limit="0.018" upper_limit="4"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:128, postvacc (N=156,157,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="87" upper_limit="96"/>
                    <measurement group_id="O2" value="75" lower_limit="68" upper_limit="82"/>
                    <measurement group_id="O3" value="88" lower_limit="82" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>four fold rise (N=132,140,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86" lower_limit="79" upper_limit="92"/>
                    <measurement group_id="O2" value="91" lower_limit="86" upper_limit="95"/>
                    <measurement group_id="O3" value="96" lower_limit="92" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:8, prevaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>63</ci_lower_limit>
            <ci_upper_limit>78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:8, one month postvaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:8, prevaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:8, one month postvaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:128, prevaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24</ci_lower_limit>
            <ci_upper_limit>39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:128, one month postvaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage difference</param_type>
            <param_value>1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2</ci_lower_limit>
            <ci_upper_limit>4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:128, prevaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3</ci_lower_limit>
            <ci_upper_limit>11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (rSBA ≥1:128, one month postvaccination), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22</ci_lower_limit>
            <ci_upper_limit>-5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (four-fold rise in titers), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17</ci_lower_limit>
            <ci_upper_limit>-4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For the comparisons to MenC based on percentages of subjects with response (four-fold rise in titers), MenACWY-CRM197 was determined to be non-inferior to MenC if the lower limit of the two-sided 95% CI for the difference between MenACWY-CRM197 and MenC in the percentage of subjects with response against serogroup C was greater than -10%.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC).</non_inferiority_desc>
            <param_type>Percentage Difference</param_type>
            <param_value>-5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11</ci_lower_limit>
            <ci_upper_limit>1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128, and Four Fold Rise Against N.Meningitidis Serogroup A, W, Y</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.
Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.</description>
        <time_frame>1 month postvaccination.</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Rabbit Serum Bactericidal ≥ 1:8, ≥ 1:128, and Four Fold Rise Against N.Meningitidis Serogroup A, W, Y</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.
Immunogenicity of two doses of MenACWY-CRM197 vaccine to one dose of MenC vaccine one month post vaccination was assessed as percentages of subjects with serum bactericidal titer with rabbit complement (rSBA) ≥ 1:8, ≥ 1:128, and four fold rise in titer against N.meningitidis Serogroup A, W, Y.</description>
          <population>Analysis was done on PP set.</population>
          <units>Percentages of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rSBA titer ≥ 1:128, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:128, Men W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="89" upper_limit="99"/>
                    <measurement group_id="O2" value="93" lower_limit="85" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:128, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="80" upper_limit="95"/>
                    <measurement group_id="O2" value="86" lower_limit="76" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:8, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="98" lower_limit="92" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:8, Men W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="95" upper_limit="100"/>
                    <measurement group_id="O2" value="95" lower_limit="88" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rSBA titer ≥ 1:8, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="91" upper_limit="100"/>
                    <measurement group_id="O2" value="88" lower_limit="79" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Fold Rise of rSBA titer, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="64" upper_limit="85"/>
                    <measurement group_id="O2" value="95" lower_limit="88" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Fold Rise of rSBA titer, Men W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="86" upper_limit="99"/>
                    <measurement group_id="O2" value="95" lower_limit="87" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Four Fold Rise of rSBA titer, Men Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="75" upper_limit="98"/>
                    <measurement group_id="O2" value="87" lower_limit="74" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.</description>
        <time_frame>1 month postvaccination.</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup C</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.
Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup C.</description>
          <population>Analysis was done on PP set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT, prevacc (N=140,140,139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="21" upper_limit="33"/>
                    <measurement group_id="O2" value="2.22" lower_limit="1.76" upper_limit="2.8"/>
                    <measurement group_id="O3" value="2.03" lower_limit="1.62" upper_limit="2.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT, postvacc (N=156,157,145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353" lower_limit="260" upper_limit="479"/>
                    <measurement group_id="O2" value="131" lower_limit="98" upper_limit="176"/>
                    <measurement group_id="O3" value="266" lower_limit="197" upper_limit="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For comparison of the Geometric Mean Titers at one month postvaccination at 12 months of age, MenACWY–CRM197 was determined to be non-inferior to MenC if the lower limit of the 2-sided 95% CI for the ratio of the MenACWY-CRM197 to MenC Geometric Mean Titers for serogroup C was greater than 0.5.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>(PConcomitant Vaccine + MenACWY-CRM - PConcomitant Vaccine + MenC)</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup A, W, Y</title>
        <description>Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with GMT of SBA with rabbit complement (rSBA) against Serogroup A, W, Y.
Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup A, W, Y.</description>
        <time_frame>1 month postvaccination.</time_frame>
        <population>Analysis was done on PP set.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rabbit Serum Bactericidal Activity Geometric Mean Titers Against N.Meningitidis Serogroup A, W, Y</title>
          <description>Immunogenicity of one dose of MenACWY-CRM197 to one dose of MenC vaccine at 12 months of age was assessed with GMT of SBA with rabbit complement (rSBA) against Serogroup A, W, Y.
Immunogenicity of two doses of MenACWY-CRM197 to one dose of MenC vaccine at 6 to 8 and 12 months of age was assessed with geometric mean titer (GMT) of serum bactericidal assay with rabbit complement (rSBA) against Serogroup A, W, Y.</description>
          <population>Analysis was done on PP set.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT, prevacc, Men A (N=73,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281" lower_limit="134" upper_limit="587"/>
                    <measurement group_id="O2" value="6.83" lower_limit="3.34" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT, postvacc, Men A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3136" lower_limit="2013" upper_limit="4886"/>
                    <measurement group_id="O2" value="3258" lower_limit="2113" upper_limit="5022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT, prevacc, Men W (N=59,75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="33"/>
                    <measurement group_id="O2" value="2.32" lower_limit="1.46" upper_limit="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT, postvacc, Men W</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="708" lower_limit="421" upper_limit="1191"/>
                    <measurement group_id="O2" value="1306" lower_limit="786" upper_limit="2169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT, prevacc, Men Y (N=32,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="12" upper_limit="40"/>
                    <measurement group_id="O2" value="2.4" lower_limit="1.42" upper_limit="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT, postvacc, Men Y (N=76,81)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="574" lower_limit="320" upper_limit="1028"/>
                    <measurement group_id="O2" value="598" lower_limit="336" upper_limit="1066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 to Day 7 Postvaccination), After Any Vaccination</title>
        <description>Safety was assessed as the number of subjects who reported solicited local reactions from day 1 to day 7 postvaccination for all the three vaccination groups.
safety was assessed as the number of subjects who reported solicited systemic reactions from day 1 to day 7 Following the Month 12 vaccination in all three vaccination groups</description>
        <time_frame>From day 1 to day 7 postvaccination</time_frame>
        <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
        <group_list>
          <group group_id="O1">
            <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
            <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O2">
            <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenACWY-CRM197 and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
          <group group_id="O3">
            <title>MenC (1dose) + Concomitant Vaccines</title>
            <description>Infants received one dose of MenC vaccine and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Reported Solicited Local and Systemic Reactions (Day 1 to Day 7 Postvaccination), After Any Vaccination</title>
          <description>Safety was assessed as the number of subjects who reported solicited local reactions from day 1 to day 7 postvaccination for all the three vaccination groups.
safety was assessed as the number of subjects who reported solicited systemic reactions from day 1 to day 7 Following the Month 12 vaccination in all three vaccination groups</description>
          <population>Analysis was done on the safety dataset, i.e. the subjects in the exposed population who provided postvaccination safety data.</population>
          <units>Number of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="192"/>
                <count group_id="O3" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Local N=(195,192,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="131"/>
                    <measurement group_id="O3" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (MenACWY-CRM197/MenC)N=(194,192,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (MenACWY-CRM197/MenC) N=(194,192,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (MenACWY-CRM197/MenC) N=(194,192,178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (DTPa-IPV-HepB-Hib) N=(189,190,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (DTPa-IPV-HepB-Hib)B N=(189,190,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (DTPa-IPV-HepB-Hib) N=(189,190,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness (PCV7) N=(189,190,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema (PCV7) N=(189,190,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration (PCV7) N=(189,190,176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Systemic reactions N=(195,192,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="149"/>
                    <measurement group_id="O3" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eating habits N=(189, 191,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleepiness N=(191,191,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Persistent crying N=(189,191,177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="93"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability N=(191,191,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting N=(191,191,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea N=(191,191,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash N=(191,191,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38.5C N=(191,192,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others N=(195,192,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic-Antipyretic medication N=(191,192,179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited Adverse Events (AEs) were collected from Days 1-7 after any vaccination. Other AEs and Serious AEs were collected from days 1 to 180.</time_frame>
      <desc>Data collected from one site were not included in the data analysis for outcome measures and the AE section.</desc>
      <group_list>
        <group group_id="E1">
          <title>MenACWY-CRM197 (2dose) + Concomitant Vaccines</title>
          <description>Infants received two doses of MenACWY-CRM197 at 6-8 months and 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
        <group group_id="E2">
          <title>MenACWY-CRM197 (1dose) + Concomitant Vaccines</title>
          <description>Infants received one dose of MenACWY-CRM197 at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
        <group group_id="E3">
          <title>MenC (1dose) + Concomitant Vaccines</title>
          <description>Infants received one dose of MenC vaccine at 12 months and Concomitant dose of PCV7 and DTPa-IPV-HepB-Hib at 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Amphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="184" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="170" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="110" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="104" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="73" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="102" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="93" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating disorder</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="179"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="195"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="192"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="179"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>GCP compliance issues were identified at one site, data collected for this site were not used in this data posting.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

